Jill Feldman: The need for accessible, patient-friendly language in treatment discussions

Jill Feldman shared on X:

“This study by Stephanie Graff and team (MUST READ for everyone) highlights the need for accessible, patient-friendly language in treatment discussions. While it focuses on metastatic Breast Cancer it’s relevant for all diseases (esp lung cancer with treatment choices based on complex, complicated, incomplete and often conflicting data!)

The study explored how concepts of clinical meaningfulness and clinically meaningful outcomes impact treatment choices for patients, caregivers and healthcare providers.

Key Findings:

Patients and caregivers were often unfamiliar with the terms.

Onc professionals knew them but rarely used in discussions.

What matters? The current focus is often OS, yet participants emphasized the importance of QOL and symptom management as vital treatment outcomes.

Key Takeaways:

A crucial gap in communication with in cancer care.

A need for a more holistic approach to treatment discussions.

Each person’s definition of ‘what is meaningful’ varies and evolves throughout their cancer experience. Adopting patient-friendly terminology and strengthening patient-clinician relationships is crucial to improve understanding and facilitate informed, patient-centered decision-making in care.”

Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery

Authors: Stephanie L. Graff, Emily C. Freeman, Meaghan Roach, Rozanne Wilson, Claire Cagle, Sarah Lunsford, Melissa Culhane Maravic, Ricki Fairley, Mary Gullatte, Jeanne Stemland,  Paulina Wochal, Julie Katz, Brianna Hoffner, Julie M. Scott, Suepattra G. May,

Source: Jill Feldman/X

More posts featuring Jill Feldman on oncodaily.com

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.